40
Participants
Start Date
July 30, 2024
Primary Completion Date
August 15, 2025
Study Completion Date
October 31, 2025
WH002
"Group A(ddWH002-ddEC): Regimen for Group A during Cycles 1-Cycles 4:WH002, 260 mg/m² administered intravenously on Day 1, with a cycle length of 2 weeks (Q2W), repeated for a total of 4 cycles.~Regimen for Group A during Cycles 5-Cycles 8:~• Epirubicin Hydrochloride 90 mg/m² and Cyclophosphamide for Injection 600 mg/m², both administered intravenously on Day 1, with each cycle lasting 2 weeks (Q2W), continued for 4 consecutive cycles."
paclitaxel injection
"Group B (ddP-ddEC):~Regimen for Group B during Cycles C1-C4:~• Paclitaxel Injection (Paclitaxel®) 175 mg/m², administered intravenously on Day 1, with a cycle duration of 2 weeks (Q2W), repeated for a total of 4 cycles.~Regimen for Group B during Cycles C5-C8:~• Epirubicin Hydrochloride 90 mg/m² and Cyclophosphamide for Injection 600 mg/m², both administered intravenously on Day 1, with cycles recurring every 2 weeks (Q2W), for a series of 4 cycles."
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OTHER
Beijing Wehand-Bio Pharmaceutical Co., Ltd
INDUSTRY